Amphastar Pharmaceuticals, Inc. 8-K

What Happened Amphastar Pharmaceuticals, Inc. (AMPH) filed an 8-K reporting that on July 9, 2026 its Board increased the authorized number of directors from ten to eleven and appointed Anthony Pierce as a Class III director effective immediately. Mr. Pierce will serve until the Company’s 2028 annual meeting of stockholders (or until his earlier death, resignation or removal). The Board determined he is independent under Nasdaq standards and he was not assigned to any Board committees at the time of appointment.

Key Details

• Board size increased from 10 to 11 directors; appointment effective July 9, 2026.
• Term: serves through the 2028 annual meeting of stockholders.
• Compensation: $55,000 annual cash retainer (pro‑rated for start date) plus an initial equity grant with aggregate fair value of $300,000 (50% restricted stock units, 50% stock options) that vests on the first anniversary, subject to continued service.
• No relationships, arrangements, or reportable transactions between Mr. Pierce and the Company; Company will enter its standard indemnification agreement.

Why It Matters This filing signals a board expansion and the addition of an independent director, which can affect corporate governance and oversight. The disclosed compensation is consistent with Amphastar’s non-employee director pay practices and there are no disclosed related-party transactions tied to the appointment, reducing immediate governance risk for investors. (Item 5.02 report of director appointment.)